# Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

> **NCT04996017** · PHASE3 · RECRUITING · sponsor: **Gruppo Oncologico Italiano di Ricerca Clinica** · enrollment: 162 (estimated)

## Conditions studied

- Mesotheliomas Pleural

## Interventions

- **DRUG:** Atezolizumab 1200 mg in 20 ML Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04996017
- **Lead sponsor:** Gruppo Oncologico Italiano di Ricerca Clinica
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-14
- **Primary completion:** 2027-07-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996017, "Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04996017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*